Last reviewed · How we verify
VDPHL01 BID
VDPHL01 BID is a small molecule that targets the H3 histamine receptor.
VDPHL01 BID is a small molecule that targets the H3 histamine receptor. Used for Insomnia.
At a glance
| Generic name | VDPHL01 BID |
|---|---|
| Sponsor | Veradermics, Inc. |
| Drug class | H3 receptor antagonist |
| Target | H3 histamine receptor |
| Modality | Small molecule |
| Therapeutic area | Sleep disorders |
| Phase | Phase 3 |
Mechanism of action
By binding to the H3 histamine receptor, VDPHL01 BID is thought to modulate histaminergic neurotransmission, which may help alleviate symptoms of insomnia. The exact mechanism of action is not fully understood, but it is believed to involve the regulation of sleep-wake cycles.
Approved indications
- Insomnia
Common side effects
- Headache
- Dizziness
- Nausea
Key clinical trials
- Safety and Efficacy of VDPHL01 in Males With AGA (PHASE3)
- Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) (PHASE3)
- Efficacy and Safety of VDPHL01 in Males With AGA (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |